RN6G

BIOLOGICAL3 trials

Sponsors

Pfizer

Conditions

Age-Related MaculopathiesAge-Related MaculopathyEye DiseasesMacular DegenerationRetinal Degeneration

Phase 1

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

CompletedNCT00877032

PfizerAge-Related Maculopathies, Age-Related Maculopathy, Eye Diseases +2

Start: 2009-04-30End: 2011-07-31Updated: 2015-03-31

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

CompletedNCT01003691

PfizerAge-Related Maculopathies, Age-Related Maculopathy, Eye Diseases +2

Start: 2010-08-05End: 2013-04-19Updated: 2022-05-12

Phase 2

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

TerminatedNCT01577381

PfizerAge-Related Maculopathy

Start: 2012-08-31End: 2013-10-31Updated: 2016-03-16